All In MedTech

Device Trial Radar · NCT07663487

A Study Evaluating the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres to Bridge or Downstage Patients With Hepatocellular Carcinoma (HCC) to Liver Transplant or Resection and Elicit Pathologic Necrosis.

A Prospective, Multicenter, Open-label Two Cohort Study Evaluating the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres to Bridge or Downstage Patients With Hepatocellular Carcinoma (HCC) to Liver Transplant or Resection and Elicit Pathologic Necrosis.

Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Oct 2029

Study completion Oct 2029

Sponsor

Lead sponsor
Sirtex MedicalNot on our public-company list
Sponsor type
Industry
First posted
Jun 23, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical investigation involves the use of an approved medical device (SIR-Spheres®) for a new purpose in patients with certain types of liver cancer. The goal is to determine whether this treatment can help patients qualify for or maintain eligibility for a liver transplant. Participation is completely voluntary and will not affect your standard medical care. The main risks involve possible side effects related to the use of radiation in the liver, such as fatigue, abdominal pain, nausea, or changes in liver function. You may or may not benefit personally from participating in this study, but the results may help improve future treatment for others. Your doctor is inviting you to take part in this clinical investigation because you have been diagnosed with liver cancer. Your doctors will have decided that treatments designed to remove or destroy cancer completely, such as surgery or heat treatment, are not suitable for you. This clinical investigation is focused on testing how well selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90 resin microspheres ("SIR-Spheres") work, its potential benefits, its safety, and finding out if there are any bad effects when it's used like it's supposed to be used. For more information, please see the section on the purpose of the clinical investigation. This Patient Informed Consent Form (PIC) tells you about the clinical investigation. It explains the tests and treatments involved and how your information will be used. Knowing what is involved will help you decide if you want to take part in the clinical investigation.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

  • SIR-Spheres Selectively Delivered to Liver TumorDevice

    SIRT involves the following two procedural components: 1. Embolization: Injection into the distal arterial tumor feeding vessels of microspheres (SIR-Spheres), which act as the delivery vehicle for the therapeutic moiety Y-90, and 2. Irradiation: Once located in the distal microvasculature of the tumor, SIRSpheres deliver high dose beta irradiation to the tumor microvascular plexus and to tumor cells directly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the proportion of subjects in both cohorts eligible for liver transplant or resection through 6 months following treatment with SIR-Spheres Y-90 resin microspheres.Time frame: 6mth Efficacy, 15mth Safety

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.